Home
Resources
Publications
Drug Evaluation: Pumosetrag for the Treatment of Irritable Bowel Syndrome and Gastroesophageal Reflux Disease

Drug Evaluation: Pumosetrag for the Treatment of Irritable Bowel Syndrome and Gastroesophageal Reflux Disease

Stefano Evangelista

Curr Opin Investig Drugs. 2007 May;8(5):416-22.

PMID: 17520871

Abstract:

Dynogen Pharmaceuticals Inc, under license from Mitsubishi Pharma Corp, is developing pumosetrag (MKC-733, DDP-733), an orally available gastroprokinetic agent and locally acting 5-HT3 partial agonist, for the potential treatment of irritable bowel syndrome (IBS) with constipation and nocturnal gastroesophageal reflux disease (GERD). In September 2005, Dynogen commenced a phase II proof-of-concept trial of pumosetrag in IBS with constipation; positive results were reported in February 2007 and a phase IIb trial was to start in the fourth quarter of 2007. In September 2006, the company had initiated a phase Ib trial in nocturnal GERD.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP194093420	MKC-733		194093-42-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: